CN1289597A - Medicine for treating fungus diseases - Google Patents
Medicine for treating fungus diseases Download PDFInfo
- Publication number
- CN1289597A CN1289597A CN 99112469 CN99112469A CN1289597A CN 1289597 A CN1289597 A CN 1289597A CN 99112469 CN99112469 CN 99112469 CN 99112469 A CN99112469 A CN 99112469A CN 1289597 A CN1289597 A CN 1289597A
- Authority
- CN
- China
- Prior art keywords
- medicament
- hydrogen peroxide
- silver
- synergist
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A medicine for treating fungus diseases is prepared from hydrogen peroxide (0.01-35 wt%), synergist (oxide or salt of silver) (0.0001-0.5), stabilizer chosen from polyphoshate, metaphosphate and pyrophosphate (0.0002-1) and pH regulator and water (rest). It is an exterior-applied medicine for different kinds of ringworms. Its advantages include no poison and environmental pollution, high curative effect and low irritation to skin.
Description
The present invention relates to a kind of mycotic medicament of the composite treatment of chemical constituent that utilizes.
Mycosis than higher, has a strong impact on people's orthobiosis and healthy by the fungus-caused tinea manuum, tinea pedis, tinea capitis, tinea corporis, tinea cruris, tinea versicolor, tinea unguium etc. at the sickness rate of China.Along with living standards of the people improve constantly, a lot of unscientific dietary habit have appearred, make the body nutrient imbalance, cause Abwehrkraft des Koepers to descend, influenced the defensive ability/resistance ability that skin stimulates to external world, dermatophytes is invaded easily.Simultaneously, unscientific hygienic habit also often causes mycotic generation.At present, prevent and to treat mycotic medicament also many, effect is different.
The purpose of this invention is to provide a kind of is the mycotic medicament of treatment of main component with the hydrogen peroxide, nontoxic, little to skin irritation, effective.
The mycotic medicament of treatment of the present invention, comprise hydrogen peroxide, synergist, stabilizing agent, it is characterized in that by weight percentage, hydrogen peroxide by 0.01～35%, 0.0001～0.5% synergist, 0.0002～1.0% stabilizing agent, the water of surplus and acid number regulator are formed, synergist is the oxide or the silver salt of silver, and stabilizing agent is selected from polyphosphate, metaphosphate, pyrophosphate, and it is 1～6 that the acid number regulator makes the pH value of medicament.
The better composition of above-mentioned each composition is: the hydrogen peroxide by 0.05～28%, and 0.0002～0.2% synergist, 0.0004～0.3% stabilizing agent, the water of surplus and acid number regulator are formed, and the PH of medicament is 2.0～5.0.
Above-mentioned synergist can be silver nitrate, silver sulfate, silver oxide, is preferably silver nitrate; Stabilizing agent can be a kind of in sodium tripolyphosphate, PTPP (potassium tripolyphosphate), sodium hexameta phosphate, hexa metaphosphoric acid potassium, tetrasodium pyrophosphate, the potassium pyrophosphate, is preferably sodium hexameta phosphate, hexa metaphosphoric acid potassium.The acid number regulator be regulate medicament PH between 1～6, can be inorganic phosphate, nitric acid, sulphuric acid, organic acid, preferably inorganic phosphate.
Best composition of the present invention is: the hydrogen peroxide by 0.05～28%, and 0.0002～0.2% silver nitrate, 0.0004～0.3% sodium hexameta phosphate (potassium), the water of surplus and phosphoric acid are formed, and it is 2.0～5.0 that phosphoric acid makes the PH of medicament.
The present invention is main component with the hydrogen peroxide, and compound synergic agent and stabilizing agent can be killed fungus, and its effect is: the permeability barrier of destroy microorganisms; The protein of destroy microorganisms, aminoacid and DNA finally cause fungus death.Proof was handled Candida albicans 30 minutes to 2 hours with the present invention by experiment, can be from the electron microscopic observation to the cell wall and cell membrane destroy, plasmolysis, high electron density precipitate reduce or disappear, the acid phosphatase reaction thing obviously reduces.
The medicament that the present invention forms is an external used medicine, can be according to the state of an illness, and wiping affected part or immersion after being diluted to finite concentration.The content of hydrogen peroxide will can not directly use through dilution when medicament uses at 5.6～35% o'clock, generally by weight, can be diluted with water to 50～300 times.This medicament itself is nontoxic, tasteless, nuisanceless, Organic substance is less to its sterilization influence, the product of low concentration is little to skin irritation, by good effects such as the fungus-caused tinea manuum, tinea pedis, tinea capitis, tinea corporis, tinea cruris, tinea versicolor, tinea unguium, is the medicament that is fit to external preparation for skin to treatment.Below be the clinical efficacy comparison report:
True and reliable in order to prove medicament of the present invention, patients such as adversary, foot, tinea corporis have carried out the test of many cases clinical treatment, have proved its good result aspect fungus.
One, case is selected:
Be comparatively universal phenomenon in dermatosiss such as the fungus-caused hands of China, foot, tinea corporis, among the crowds such as old age, middle age, youth this patient of many trouble arranged all, the masculinity and femininity crowd distributes also comparatively extensive.Therefore, select male's 60 examples, women's 56 examples amount to 116 examples; Wiping type tinea pedis person 50 examples in the middle of it, vesicular tinea manuum person 36 examples, tinea corporis person's 30 examples, all belong to serious symptom and in light disease state of an illness performance.
Two, diagnostic criteria:
Between wiping type hands, tinea pedis: generally violate in third and fourth toe or between referring to, acute pruritus, skin lesion is dipping, erosion, can cause bacillary secondary infection, if inflammation is not controlled, can cause some complication, as lymphatic vessel (knot) inflammation.
Blister type hands, tinea pedis: diseased region is common in toes and sufficient edge or palm and refers to abdominal part, is the vesicle of trooping or being dispersed in, and limpid vesicle fluid is yellow-white, with pruritus.
Tinea corporis: can betide any level and smooth skin part, be many with hyperhidrosis or damp and hot position.Beginning is to occur one or several little red pimple or blister on the skin, to increasing expansion gradually all around, can generally send to whole body sometimes thus.
Serious symptom: patient's play is itched unbearably, and the skin lesion place is red and swollen, rotten to the corn, ooze out obviously, and with inflammation.
In light disease: the patient feels pruritus, the red and swollen and local shallow top layer erosion in skin lesion place, NIP.
Three, therapeutic scheme:
Divide contrast groups and treatment group.Contrast groups is the medicament " anti-tinea spirit " of treatment hands commonly used, foot, tinea corporis, and the treatment group is a medicament of the present invention.116 examples are organized in treatment, contrast groups 95 examples.
Treatment group, the weight content of hydrogen peroxide are 5.5%, and medicament is with 50 times (weight ratio) of clean water dilution, and soaked 5 minutes at every turn in adversary, tinea pedis affected part, patient with severe symptoms every day 2 times, in light patient every day 1 time; Tinea corporis patient is with 5 times of clean water dilutions, wiping affected part, every day 2 times.All be 5 days the above course of treatment.
Contrast groups is used by its operation instruction, and 5 days is a course of treatment.
Four, efficacy assessment standard:
Cure: no pruritus, the skin lesion place is as excellent as before, has inflammation person to disappear.
Sx: slight redness is arranged, and the original area in skin lesion place reduces more than 2/3, does not have rotten to the corn face, NIP.
Invalid: original various symptoms do not change.
Five: the clinical treatment result:
Table one: treatment group therapeutic effect
Table two: contrast groups therapeutic effect
Six, conclusion
| Type | The case sum | Sex | The example number | Disease example number | Therapeutic outcome | ||||||
| Heavy | In light | Cure | Cure rate % | Sx | Sx rate % | Invalid | Total effective rate % | ||||
| Between wiping type tinea pedis | 50 | The man | 25 | ?14 | ?11 | ?35 | ?70 | ?15 | ?30 | ?0 | ?100 |
| The woman | 25 | ?12 | ?13 | ||||||||
| Vesicular tinea manuum | 36 | The man | 20 | ?13 | ?7 | ?24 | ?66.7 | ?12 | ?33.3 | ?0 | ?100 |
| The woman | 16 | ?11 | ?5 | ||||||||
| Tinea corporis | 30 | The man | 15 | ?6 | ?9 | ?18 | ?60 | ?12 | ?40 | ?0 | ?100 |
| The woman | 15 | ?5 | ?10 | ||||||||
| Add up to | 116 | ?61 | ?55 | ?77 | ?66.4 | ?39 | ?33.6 | ?0 | ?100 | ||
| Type | The case sum | Sex | The example number | Disease example number | Therapeutic outcome | ||||||
| Heavy | In light | Cure | Cure rate % | Sx | Sx rate % | Invalid | Total effective rate % | ||||
| Between wiping type tinea pedis | 35 | The man | 20 | ?13 | ?7 | ?19 | ?54.3 | ?12 | ?34.3 | ?4 | ?87.6 |
| The woman | 15 | ?7 | ?8 | ||||||||
| Vesicular tinea manuum | 30 | The man | 15 | ?8 | ?7 | ?15 | ?50.0 | ?11 | ?36.7 | ?4 | ?86.7 |
| The woman | 15 | ?9 | ?6 | ||||||||
| Tinea corporis | 30 | The man | 15 | ?5 | ?10 | ?13 | ?43.3 | ?12 | ?40.0 | ?5 | ?83.3 |
| The woman | 15 | ?4 | ?11 | ||||||||
| Add up to | 95 | ?46 | ?49 | ?47 | ?49.5 | ?35 | ?36.8 | ?13 | ?86.3 | ||
The present invention passes through 116 routine patient treatments, and total effective rate is 100%, cure rate 66.4%, sx rate 33.6%.And the contrast groups total effective rate is 86.3%, cure rate 49.5%, sx rate 36.8%.From the clinical therapeutic efficacy analysis, no matter the present invention is to a wiping type tinea pedis, still vesicular tinea manuum and tinea corporis all have the obvious treatment effect, thereby are the medicaments of a kind of quick and effective treatment hands, foot, body, head, tinea cruris and tinea versicolor, tinea unguium, for the treatment mycosis has increased a kind of new drug again.
Embodiment one:
0.028% hydrogen peroxide, 0.0013% silver nitrate, 0.0021% sodium hexameta phosphate, water and phosphoric acid mix, and PH is 2.
Embodiment two:
0.8% hydrogen peroxide, 0.05% silver nitrate, 0.05% sodium hexameta phosphate, water and phosphoric acid mix, and PH is 3.
Embodiment three:
2% hydrogen peroxide, 0.1% silver nitrate, 0.1% sodium hexameta phosphate, water and phosphoric acid mix, and PH is 1.5.
Embodiment four:
0.112% hydrogen peroxide, 0.00052% silver nitrate, 0.00084% sodium hexameta phosphate, water and phosphoric acid mix, and PH is 4.
Embodiment five:
1.12% hydrogen peroxide, 0.0052% silver nitrate, 0.0084% sodium hexameta phosphate, water and phosphoric acid mix, and PH is 5.
Embodiment six:
5.5% hydrogen peroxide, 0.026% silver nitrate, 0.042% sodium hexameta phosphate, water and phosphoric acid mix, and PH is 3.5.
Embodiment seven:
15% hydrogen peroxide, 0.2% silver nitrate, 0.2% sodium hexameta phosphate, water and phosphoric acid mix, and PH is 4.5.
Embodiment eight:
28% hydrogen peroxide, 0.5% silver oxide, 0.6% sodium hexameta phosphate, water and phosphoric acid mix, and PH is 3.
Embodiment nine:
0.56% hydrogen peroxide, 0.0026% silver oxide, 0.0042% PTPP (potassium tripolyphosphate), water and nitric acid mix, and PH is 4.
Embodiment ten:
0.01% hydrogen peroxide, 0.0001% silver sulfate, 0.0008% tetrasodium pyrophosphate, water and sulphuric acid mix, and PH is 5.
Embodiment 11:
20% hydrogen peroxide, 0.5% silver nitrate, 1% hexa metaphosphoric acid potassium, water and phosphoric acid mix, and PH is 1.
Embodiment 12:
35% hydrogen peroxide, 0.3% silver sulfate, 0.05% potassium pyrophosphate, water and phosphoric acid mix, and PH is 6.
Claims (5)
1, the mycotic medicament of a kind of treatment, comprise hydrogen peroxide, synergist, stabilizing agent, it is characterized in that by weight percentage, hydrogen peroxide by 0.01～35%, 0.0001～0.5% synergist, 0.0002～1.0% stabilizing agent, the water of surplus and acid number regulator are formed, synergist is the oxide or the silver salt of silver, and stabilizing agent is selected from polyphosphate, metaphosphate, pyrophosphate, and it is 1～6 that the acid number regulator makes the pH value of medicament.
2, medicament according to claim 1 is characterized in that by 0.05～28% hydrogen peroxide, 0.0002～0.2% synergist, and 0.0004～0.3% stabilizing agent, the water of surplus and acid number regulator are formed, and the pH value of medicament is 2.0～5.0.
3, medicament according to claim 1 and 2 is characterized in that the acid number regulator is inorganic phosphate or nitric acid, sulphuric acid, is preferably inorganic phosphate.
4, medicament according to claim 1 and 2, it is characterized in that synergist is silver oxide, silver nitrate, silver sulfate, be preferably silver nitrate, stabilizing agent can be a kind of in sodium tripolyphosphate, PTPP (potassium tripolyphosphate), sodium hexameta phosphate, hexa metaphosphoric acid potassium, tetrasodium pyrophosphate, the potassium pyrophosphate, is preferably sodium hexameta phosphate, hexa metaphosphoric acid potassium.
5, medicament according to claim 4, it is characterized in that by 0.05～28% hydrogen peroxide 0.0002～0.2% silver nitrate, 0.0004～0.3% sodium hexameta phosphate or hexa metaphosphoric acid potassium, the water of surplus and phosphoric acid are formed, and it is 2.0～5.0 that phosphoric acid makes the PH of medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99112469A CN1114417C (en) | 1999-09-29 | 1999-09-29 | Medicine for treating fungus diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99112469A CN1114417C (en) | 1999-09-29 | 1999-09-29 | Medicine for treating fungus diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1289597A true CN1289597A (en) | 2001-04-04 |
| CN1114417C CN1114417C (en) | 2003-07-16 |
Family
ID=5275773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99112469A Expired - Fee Related CN1114417C (en) | 1999-09-29 | 1999-09-29 | Medicine for treating fungus diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1114417C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101389221B (en) * | 2005-01-05 | 2012-06-13 | 罗伯特·霍拉迪 | Silver/water, silver gels and silver-based compositions, method for fabricating and using the same |
| CN104490970A (en) * | 2014-12-25 | 2015-04-08 | 李健 | Medicament composition for treating tinea corporis and preparation method of medicament composition |
| CN109757515A (en) * | 2019-03-18 | 2019-05-17 | 洛阳民康生物工程有限公司 | A kind of colorless and transparent micromicron grade electrolytic silver ion complex antimicrobials and preparation method thereof |
| CN111450114A (en) * | 2020-05-21 | 2020-07-28 | 苏州汇涵医用科技发展有限公司 | Compound disinfectant liquid containing hydrogen peroxide and silver ions and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04321628A (en) * | 1991-04-18 | 1992-11-11 | Kanebo Ltd | Antimicrobial agent consisting of colloid particle of silver |
| DE19640364A1 (en) * | 1996-09-30 | 1998-04-02 | Basf Ag | Topical agents for the prophylaxis or treatment of bacterial skin infections |
| CN1178232A (en) * | 1996-09-30 | 1998-04-08 | 巴斯福股份公司 | Polymer/hydrogen peroxide complexes |
-
1999
- 1999-09-29 CN CN99112469A patent/CN1114417C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101389221B (en) * | 2005-01-05 | 2012-06-13 | 罗伯特·霍拉迪 | Silver/water, silver gels and silver-based compositions, method for fabricating and using the same |
| CN104490970A (en) * | 2014-12-25 | 2015-04-08 | 李健 | Medicament composition for treating tinea corporis and preparation method of medicament composition |
| CN109757515A (en) * | 2019-03-18 | 2019-05-17 | 洛阳民康生物工程有限公司 | A kind of colorless and transparent micromicron grade electrolytic silver ion complex antimicrobials and preparation method thereof |
| CN111450114A (en) * | 2020-05-21 | 2020-07-28 | 苏州汇涵医用科技发展有限公司 | Compound disinfectant liquid containing hydrogen peroxide and silver ions and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1114417C (en) | 2003-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pegram et al. | Successful ketoconazole treatment of protothecosis with ketoconazole-associated hepatotoxicity | |
| CN1308027C (en) | Medicinal formulation for treating skin tinea | |
| JP2020505427A (en) | How to treat fungal infections | |
| CN1114417C (en) | Medicine for treating fungus diseases | |
| US7258876B2 (en) | Topical composition for treating infectious conditions of skin and mucosa | |
| CN1136003C (en) | Exterior-applied ointment for treating dermatitis | |
| Crosier et al. | Onychomycosis due to Pityrosporum | |
| CLAYTON et al. | A clinical double‐blind trial of topical miconazole* and clotrimazole† against superficial fungal infections and erythrasma | |
| EP1374903B1 (en) | Pharmaceutical composition for the prevention of the development and progression of mycotic skin surface diseases | |
| Clayton et al. | Double blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma | |
| CN107233335A (en) | Perillaldehyde is preparing the purposes in preventing and treating the medicine of vaginitis | |
| CN1177587C (en) | Riluzole and alpha-tocopherol combination | |
| Adewale et al. | Effects of a single pill 3-drug combination of lamivudine, nevirapine and zidovudine on blood parameters and liver histology in female wistar rats | |
| CN1247227C (en) | External-use liposome prepn for treating mite-borne dermatosis | |
| CN1103218C (en) | Ointment for treating dermatosis and its preparation | |
| CN1056774C (en) | Keyoulin sterilizing bactericide | |
| CN1989813A (en) | Pyridaphenthion-avermectin compound agent | |
| CN109758551B (en) | A Chinese medicinal composition for treating tinea pedis and vulvovaginal candidiasis | |
| Raimalani et al. | A look into dark side of fungal agents: researches on human diseases | |
| EP1487440B1 (en) | A use of a synergistic formulation of antifungal agents for the treatment of fungal infections | |
| JPH0124136B2 (en) | ||
| CN117180343A (en) | Traditional Chinese medicine composition for treating dermatophytosis and application thereof | |
| CN1182854C (en) | Chinese medicine liquor for curing pointed condyloma | |
| CN101002823A (en) | External use medicine for treating finger nail (ortoenail) mycosis | |
| WO2022051671A1 (en) | Mineral cation complex compositions, formulations therof, and methods of use therof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |